The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review

This publication has 41 references indexed in Scilit:

• Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials
  Annals of Oncology, 2014
• Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer
  Clinical Genitourinary Cancer, 2014
• A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)
  Journal of Translational Medicine, 2014
• Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy
  Clinical Genitourinary Cancer, 2013
• Prognostic Factors in Patients with Advanced Cancer: A Comparison of Clinicopathological Factors and the Development of an Inflammation-Based Prognostic System
  Clinical Cancer Research, 2013
• The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
  Critical Reviews in Oncology/Hematology, 2013
• The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
  Cancer Treatment Reviews, 2013
• Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer
  Cancer Chemotherapy and Pharmacology, 2013
• Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy
  Journal of Cancer Research and Clinical Oncology, 2012
• The economics of cancer care in the UK
  The Lancet Oncology, 2004